Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
about
Pathogenic LRRK2 negatively regulates microRNA-mediated translational repressionRibosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's diseaseMKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junctionHexokinase activity is required for recruitment of parkin to depolarized mitochondriaDysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegansLoss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxiaPharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.mTOR is a key modulator of ageing and age-related diseasePrimary skin fibroblasts as a model of Parkinson's diseaseMitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorderHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsShedding new light on neurodegenerative diseases through the mammalian target of rapamycinIs inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?Fine-Tuning of PI3K/AKT Signalling by the Tumour Suppressor PTEN Is Required for Maintenance of Flight Muscle Function and Mitochondrial Integrity in Ageing Adult Drosophila melanogasterPathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvationTranslation initiator EIF4G1 mutations in familial Parkinson diseaseRTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disordersAlleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegenerationRapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathyLoss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome cThe Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylationERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyIdentification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy.Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster.Parkinson's disease: insights from pathways.Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death.Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.Drosophila melanogaster in the study of human neurodegeneration.RNA metabolism in the pathogenesis of Parkinson׳s diseaseRecent advances in the genetics of Parkinson's disease.Role of LRRK2 kinase dysfunction in Parkinson diseaseTOR and ageing: a complex pathway for a complex process.Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.Role of TOR signaling in aging and related biological processes in Drosophila melanogasterBiosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismateDrosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies.Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.Genome-wide screen for modifiers of Parkinson's disease genes in Drosophila.
P2860
Q24293587-643B146B-6063-4EBA-968B-FAB759B4BE54Q24294458-86724017-903C-4DAD-81E1-DACF493FC015Q24294736-78549DF7-AE0F-40DA-90E4-D5FA5370E067Q24316894-0FDDFBEE-AC97-43F8-BFD7-EF5A5BCA25D9Q24318901-5663D625-9C02-4020-81B3-32546676BFC5Q24324231-50E295DD-FBAB-4160-AF56-D5EB167AD8DCQ24337840-95CF73E5-B277-4FC0-A820-5F4D41B93940Q24339508-67C1B3F9-7286-4DDF-8A94-A14F2A9630DEQ24610741-6879DFA7-E7DE-476F-B627-E958F8362F0BQ26999310-09C482A1-7E20-4104-8206-663300EE87DFQ27001551-5826F635-84F7-4AE5-BAB6-93D085DC80B9Q27013695-7EE866DB-5A80-40F9-A8A8-45C8A3BE715EQ27015640-CC8E3661-F698-4141-8200-B043318F366EQ27026262-95246AD7-3463-4CA0-AB9D-300923836155Q27337692-A67C79CD-6BF8-4B62-9B68-782206D992A7Q28115231-2059BE62-08A1-47C0-B929-B8A16777184BQ28247679-F9B6759B-8515-40E0-AC88-B76879B690E6Q28395230-589C0E1C-D598-4C5E-8DF8-2AAEF9D7E115Q28834138-CACC70AF-110A-4884-8DDF-B900A29CF69DQ30662442-691856D9-DA89-4404-A1B8-FF1A9F2191AEQ30855422-CABC97B2-050F-48C1-A66F-41E0CFB8DAF2Q33525587-A1907C94-2EC4-48EC-B532-19A01CE9AEAEQ33593798-D22E172F-452A-4091-BB7D-3066901FEE58Q33670282-2202DED2-9386-464D-BB2E-1736C2336082Q33732095-6ECFAE82-AD40-4304-9DF9-5E5B70C819B4Q33769106-DCD97DD6-75B6-4564-8D41-A19AE9DD392DQ33871291-F554701C-4B44-4691-9141-FF2C4D593B49Q33889585-294510A1-CC1B-43A5-8B6C-F2E28B5E0605Q33964804-6BD615A7-F661-4A4A-9BC8-70029D1FDE49Q34022667-AD4CFC7B-042E-4A58-A9FB-1BACE8C73A50Q34175642-C022F2B3-9B89-49CF-929A-8A2AFF8732B1Q34189660-449BFBB7-13EA-4DD9-8E22-D580F5398DB2Q34192817-4CAF99C1-0DBC-441F-9667-833EC0F35BE3Q34402682-DD910173-7D71-4592-8159-1463DBDD502AQ34452296-57FB2EA0-A41B-451C-BFBD-5EDF8AE29898Q34677806-2E6CFBBB-7990-42EE-A86C-FA416349D78FQ34720963-5CDD8F4E-2CE4-42D4-8CA2-7DF1E126B1EEQ34787767-73D0916E-AA7A-457E-88FB-E34AA6AD1FDDQ34977478-86F28B11-F083-4E1B-A6E3-BEACB8AFFDDBQ34980547-DD37A35E-10C1-4BAF-972C-996E9709E37A
P2860
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
@en
type
label
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
@en
prefLabel
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.
@en
P2860
P50
P356
P1433
P1476
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
@en
P2093
Elena Ziviani
P2860
P2888
P304
P356
10.1038/NN.2372
P407
P577
2009-08-16T00:00:00Z
P5875
P6179
1008140346